MA31400B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA31400B1
MA31400B1 MA32385A MA32385A MA31400B1 MA 31400 B1 MA31400 B1 MA 31400B1 MA 32385 A MA32385 A MA 32385A MA 32385 A MA32385 A MA 32385A MA 31400 B1 MA31400 B1 MA 31400B1
Authority
MA
Morocco
Prior art keywords
organic compounds
formula
disorders
compound
tautomers
Prior art date
Application number
MA32385A
Other languages
Arabic (ar)
English (en)
Inventor
Robin Alec Fairhurst
Rebecca Butler
Paul Oakley
Stephen Paul Collingwood
Nichola Smith
Emily Stanley
Perez Maria Ines Rodriguez
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31400B1 publication Critical patent/MA31400B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un composé de formule (i) ou ses tautomères, ses stéréoisomères, ses solvates ou ses sels pharmaceutiquement acceptables. Dans la formule (i), m1, m2, l1, l2, w1, w2, x1, x2, y1, y2, a, r5 et r5a sont tels que définis dans le présent document. Le composé selon l'invention est destiné au traitement de troubles qui peuvent être traités par le blocage d'un canal sodium épithélial, notamment de troubles qui bénéficient de l'hydratation mucosale.
MA32385A 2007-05-07 2009-11-30 Composes organiques MA31400B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107654 2007-05-07
PCT/EP2008/055497 WO2008135557A1 (fr) 2007-05-07 2008-05-05 Composés organiques

Publications (1)

Publication Number Publication Date
MA31400B1 true MA31400B1 (fr) 2010-05-03

Family

ID=38581916

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32385A MA31400B1 (fr) 2007-05-07 2009-11-30 Composes organiques

Country Status (31)

Country Link
US (1) US8318935B2 (fr)
EP (2) EP2332933A1 (fr)
JP (1) JP5244904B2 (fr)
KR (1) KR20100005730A (fr)
CN (1) CN101687851B (fr)
AR (1) AR066458A1 (fr)
AT (1) ATE499363T1 (fr)
AU (1) AU2008248598B2 (fr)
BR (1) BRPI0811562A2 (fr)
CA (1) CA2685546A1 (fr)
CL (1) CL2008001301A1 (fr)
CO (1) CO6290667A2 (fr)
CR (1) CR11091A (fr)
DE (1) DE602008005140D1 (fr)
EA (1) EA200901489A1 (fr)
EC (1) ECSP099718A (fr)
ES (1) ES2361595T3 (fr)
GT (1) GT200900289A (fr)
HN (1) HN2009003214A (fr)
IL (1) IL201828A0 (fr)
MA (1) MA31400B1 (fr)
MX (1) MX2009012077A (fr)
NZ (1) NZ580737A (fr)
PE (1) PE20090733A1 (fr)
PL (1) PL2155721T3 (fr)
PT (1) PT2155721E (fr)
SV (1) SV2009003406A (fr)
TN (1) TN2009000469A1 (fr)
TW (1) TWI351402B (fr)
WO (1) WO2008135557A1 (fr)
ZA (1) ZA200907491B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
WO2009139948A1 (fr) 2008-02-26 2009-11-19 Johnson Michael R Bloqueurs poly-aromatiques de canaux sodiques
KR20110085768A (ko) 2010-01-21 2011-07-27 삼성전자주식회사 Ｃｍｏｓ 이미지 센서, 상기 이미지 센서의 데이터 리드아웃 방법, 및 상기 이미지 센서를 포함하는 전자 시스템
US8372845B2 (en) * 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
AU2012331275A1 (en) 2011-11-02 2014-04-03 Boehringer Ingelheim International Gmbh Novel process for the preparation of acylguanidines and acylthioureas
NO2773633T3 (fr) * 2011-11-02 2017-12-30
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2013174757A1 (fr) 2012-05-25 2013-11-28 Boehringer Ingelheim International Gmbh Amines tertiaires, médicaments contenant lesdites amines, leur utilisation et leurs procédés de préparation
WO2014044849A1 (fr) 2012-09-24 2014-03-27 Boehringer Ingelheim International Gmbh Composés hétérocycliques, médicaments contenant ces composés, leur utilisation et procédés de leur préparation
KR102396897B1 (ko) 2012-11-02 2022-05-13 버텍스 파마슈티칼스 인코포레이티드 Ｃｆｔｒ 매개된 질환의 치료를 위한 약제학적 조성물
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
EP2991981B1 (fr) * 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Composés de diaminopyrazine, médicaments contenant lesdits composés, leur utilisation et leurs procédés de préparation
CA2915633A1 (fr) * 2013-07-02 2015-01-08 The California Institute For Biomedical Research Composes destines au traitement de la mucosviscidose
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
UY36034A (es) 2014-03-18 2015-09-30 Astrazeneca Ab Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos
WO2015145353A1 (fr) 2014-03-27 2015-10-01 Novartis Ag Dispersions d'huile-dans-l'eau solides séchées par pulvérisation pour l'inhalation de principes pharmaceutiques actifs
GB201412545D0 (en) * 2014-07-15 2014-08-27 Univ Manchester The And Manchester Metropolitan University Enzymatic processes and uses
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
US10155749B2 (en) * 2015-01-12 2018-12-18 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
US9932324B2 (en) * 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
EP3245202B1 (fr) * 2015-01-12 2020-03-11 Boehringer Ingelheim International GmbH Composés de benzimidazolium tétrasubstitué utiles pour le traitement de maladies respiratoires
US10291868B2 (en) * 2016-01-29 2019-05-14 SK Hynix Inc. Image sensing device
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
WO2018175340A1 (fr) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Conjugués d'exposition réduite modulant des cibles thérapeutiques
WO2018175302A1 (fr) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Conjugués polymères ciblant c-src à exposition réduite
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US3544571A (en) 1968-09-04 1970-12-01 Merck & Co Inc Process for making pyrazinoylthiourea compounds
US4246406A (en) 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
JP3192424B2 (ja) 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション アレルギーまたは炎症疾患の治療用化合物
WO1993019751A1 (fr) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Composes utilisables dans le traitement des maladies inflammatoires et dans l'inhibition de la production du facteur de necrose tumorale
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
KR100563395B1 (ko) 1998-06-30 2006-03-23 다우 글로벌 테크놀로지스 인크. 중합체 폴리올 및 이의 제조방법
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
PL203117B1 (pl) 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
SK286641B6 (sk) 1999-05-04 2009-03-05 Schering Corporation Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ATE390414T1 (de) * 1999-07-19 2008-04-15 Univ North Carolina Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
HUP0300832A2 (hu) 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AU2001266100B9 (en) 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
CA2417826A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1345937B1 (fr) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
SI1353919T1 (sl) 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
EP1395604B1 (fr) 2001-06-12 2008-06-25 Glaxo Group Limited 17 alpha esters heterocycliques anti-inflammatoires de derives de 17 beta carbothioate androstane
EP2039762A3 (fr) 2001-06-21 2009-07-29 Verenium Corporation Nitralases
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
RU2004110717A (ru) 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
CA2470956C (fr) 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. Derives de 1-alkyl-1- azoniabicyclo[2.2.2]octane carbamate
AU2003202044A1 (en) 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1490317A1 (fr) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
JP4324480B2 (ja) 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
WO2003086294A2 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
EP1507754A1 (fr) 2002-05-28 2005-02-23 Theravance, Inc. Agonistes du recepteur adrenergique beta 2 alcoxy aryle
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
WO2004000814A1 (fr) 2002-06-25 2003-12-31 Merck Frosst Canada & Co. Inhibiteurs de pde4 8-(biaryle)quinolines
US20060004056A1 (en) 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
US20060167001A1 (en) 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
US20060166995A1 (en) 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives
HRP20050198A2 (hr) 2002-08-10 2006-04-30 Altana Pharma Ag Piperidin-piridazoni i ftalazoni kao inhibitori pde4
WO2004018449A1 (fr) 2002-08-10 2004-03-04 Altana Pharma Ag Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4)
CA2495597A1 (fr) 2002-08-17 2004-03-04 Altana Pharma Ag Nouvelles phenanthridines
AU2003263216A1 (en) 2002-08-17 2004-03-11 Nycomed Gmbh Benzonaphthyridines with PDE 3/4 inhibiting activity
CA2496175A1 (fr) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
EP1534675B1 (fr) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
CA2496459C (fr) 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines en tant qu'inhibiteurs de pde-4
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
NZ538932A (en) 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
JPWO2004026873A1 (ja) 2002-09-18 2006-01-19 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
EP1440966A1 (fr) 2003-01-10 2004-07-28 Pfizer Limited Dérivés d'indole utilisables pour traiter des maladies
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
KR20050065624A (ko) 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
AU2004207482B2 (en) 2003-01-21 2009-10-08 Merck Sharp & Dohme Corp. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1601657A1 (fr) 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazoles, modulateurs de transporteurs de cassettes de liaison a l'atp
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
EP1636269A2 (fr) 2003-06-10 2006-03-22 Ace Biosciences A/S Polypeptides d'aspergillus extracellulaires
CA2534568A1 (fr) * 2003-08-18 2005-03-24 Parion Sciences, Inc. Bloqueurs du canal sodique a base de pyrazinoylguanidine alaphatique
EP1670474A4 (fr) * 2003-08-18 2008-08-06 Parion Sciences Inc Bloqueurs du canal sodique a pyrazinoyl-guanidine cyclique
US7973169B2 (en) 2003-09-06 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
WO2005120497A2 (fr) 2004-06-04 2005-12-22 The Regents Of The University Of California Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes
JP5385605B2 (ja) 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
CA2600869A1 (fr) 2005-03-18 2006-09-28 The Regents Of The University Of California Composes possedant une activite de correction du traitement de mutant-cftr et utilisations de ceux-ci
CA2609392A1 (fr) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs de cassette de liaison a l'atp
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости

Also Published As

Publication number Publication date
ZA200907491B (en) 2010-07-28
BRPI0811562A2 (pt) 2014-12-09
AU2008248598A1 (en) 2008-11-13
HN2009003214A (es) 2012-03-05
TWI351402B (en) 2011-11-01
CN101687851A (zh) 2010-03-31
ECSP099718A (es) 2009-12-28
TN2009000469A1 (en) 2011-03-31
EP2155721B1 (fr) 2011-02-23
AU2008248598B2 (en) 2011-11-17
GT200900289A (es) 2010-05-21
JP2010526118A (ja) 2010-07-29
PE20090733A1 (es) 2009-07-17
PL2155721T3 (pl) 2011-07-29
PT2155721E (pt) 2011-05-09
MX2009012077A (es) 2009-11-19
KR20100005730A (ko) 2010-01-15
CN101687851B (zh) 2013-02-27
AR066458A1 (es) 2009-08-19
ATE499363T1 (de) 2011-03-15
DE602008005140D1 (de) 2011-04-07
US20100105660A1 (en) 2010-04-29
HK1141285A1 (en) 2010-11-05
TW200902517A (en) 2009-01-16
CA2685546A1 (fr) 2008-11-13
IL201828A0 (en) 2010-06-16
NZ580737A (en) 2012-03-30
JP5244904B2 (ja) 2013-07-24
EP2155721A1 (fr) 2010-02-24
CO6290667A2 (es) 2011-06-20
EA200901489A1 (ru) 2010-04-30
SV2009003406A (es) 2010-01-12
EP2332933A1 (fr) 2011-06-15
CR11091A (es) 2009-12-17
CL2008001301A1 (es) 2008-12-19
ES2361595T3 (es) 2011-06-20
US8318935B2 (en) 2012-11-27
WO2008135557A1 (fr) 2008-11-13

Similar Documents

Publication Publication Date Title
MA54327B1 (fr) Inhibiteurs de kras g12c
TN2009000469A1 (en) Organic compounds
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MX2024009925A (es) Composiciones y metodos para tratar trastornos del snc.
ATE368031T1 (de) Neue gamma secretase inhibitoren
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
TW200745086A (en) Organic compounds
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MA30652B1 (fr) Composes organiques
TW200637866A (en) Amino-imidazolones for the inhibition of β-secretase
DE602004026053D1 (fr)
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA40225A (fr) Composés dihydroisoquinolinone substitués
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA31466B1 (fr) Derives de benzimidazole
MXPA05008126A (es) Inhibidores de girasa y uso de los mismos.
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA29926B1 (fr) Derives de pyrazine
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
IS7928A (is) Sertakónasóllyfjablöndur til notkunar í leggöng